FOUR MEDICINES AND THE PEOPLE THEY HELP
Research Peptide Fundamentals: research peptides treat different health needs
Scientists made peptide medicines to change how the body works. A peptide has amino acids joined together; proteins contain these same small parts. These medicines went on to treat different illnesses.
Semaglutide
Semaglutide copies GLP-1, a hormone that carries messages about sugar and hunger. Weight fell in human trials. Other tests found fewer major problems with the heart or with the kidneys.
Read the benefits and cautions →
Tirzepatide
Tirzepatide copies gut hormones including GLP-1, helping insulin lower sugar after meals. Approval covers certain sugar, weight and sleep problems.
Read the benefits and cautions →
Tesamorelin
Tesamorelin increases growth hormone, which helps your body use fat and grow. Trials measured less fat surrounding belly organs of adults with HIV. Trials haven’t established general weight loss.
Read the benefits and cautions →
PT-141
Bremelanotide treats a loss of sexual desire that causes distress in women before menopause. The approved prescription differs from a research bottle. The name PT-141 alone tells you nothing about that bottle’s quality.
Read the benefits and cautions →Approval applies to a certain treatment for certain people
Scientists sought medicines for sugar control, weight, unusual fat buildup and desire. Some became prescription treatments after tests in people. FDA approval covers a certain medicine, the form given, the illness treated and the people treated. Approval doesn't stretch to every use someone might claim for you.
Semaglutide and tirzepatide treat certain blood-sugar and weight problems. Tesamorelin reduces unusual fat buildup deep within the belly of adults with HIV [13]. PT-141 means bremelanotide, a medicine for distressing loss of desire before menopause [21]. The women had lost previously normal desire across partners and settings.
The numbers in brackets point to studies or official drug instructions. Those sources let you check what researchers tested and found. A finding may support one treatment while leaving another use untested. Your health problem needs evidence of its own, even with an approved medicine.
The people in a trial set the limits of its findings
A drug name doesn't tell you whether the treatment fits your needs. The illness tested and who took part matter just as much, because comparing treatments can show whether a drug helped beyond the changes that happened without the drug. Even many people can't answer a question the researchers never asked.
One heart study followed 17,604 adults taking semaglutide or placebo, a comparison with no active medicine [3]. Fewer serious heart problems occurred in the semaglutide group. Another trial found that major kidney problems occurred less often in 3,533 people with type 2 diabetes whose kidney disease was long-lasting [2]. In a 72-week comparison, 751 adults with obesity lost more weight with tirzepatide than semaglutide, on average [1].
Tesamorelin researchers measured fat surrounding organs in adults living with HIV [12][14][16]. Bremelanotide researchers asked women about desire and the distress of losing desire [19][20]. Those results concern the needs of the people in those trials. They don't prove claims about younger bodies or better sexual performance for you.
Body actions leave a research bottle’s contents unproven
A peptide can carry messages from one part of your body to another. Scientists can alter a peptide so your body doesn't break the peptide down as quickly. Such changes helped create the medicines discussed here. Each medicine affects a different part of how the body works.
GLP-1 helps insulin bring blood sugar down after food and helps curb hunger. Semaglutide copies GLP-1, while tirzepatide also copies GIP, another hormone helping release insulin after a meal. Tesamorelin increases growth hormone and a protein involved in growth. Bremelanotide acts inside the brain to affect sexual desire.
An approved medicine may still be tested for a new purpose, while calling a bottle a “research peptide” tells you neither whether the bottle has approval nor what the bottle contains. Research chemicals don't inherit the checks applied to prescription medicines. The approved drug behind the PT-141 name is prescription bremelanotide for a certain use [21].
You need more than a possible body action to judge a benefit. The drug and the reason for treatment need matching evidence. A result in one group leaves questions about other groups. A bottle's familiar name can't answer any of those questions for you.
Tests in animals leave the question of human benefit open
Researchers learn different things from different kinds of tests. Chance can decide treatment groups, helping make a comparison fair. A review can bring trials together, though the trials may differ. Animal experiments explore body actions; trials in people check whether people benefited during the time the researchers followed them.
Rats and mice ate differently after getting semaglutide [6]. A separate human trial counted serious heart problems [3]. Bremelanotide research includes brain scans and Phase 3 trials, large tests in people before approval [18][19]. Hamsters showed no added sign of finding sexual activity rewarding [17].
The hamster test can't tell you how a woman feels on treatment. Nor can a brain scan by itself prove relief from an illness. The comparison explains which health problems each drug was tested for. The numbered references let you find the sources of those findings.